Anu Osinusi, MD

Clinical Research
Gilead
Foster City, California, United States

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT